Results 191 to 200 of about 70,621 (279)

Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer. [PDF]

Int J Mol Med
Jung E, Kim JY, Ko D, Seo J, Lee SY, Lee D, Kim S, Park M, Kim S, Park S, Lee K, Kang YK, Nam KD, Kim YJ, Seo JH.   +14 more
europepmc   +1 more source

Light‐Activated Multifunctional Nanoplatforms: Reshaping Combination Therapy to Overcome Multidrug Resistance in Breast Cancer

Small Structures, Volume 7, Issue 3, March 2026.
Multidrug resistance in breast cancer constitutes a major therapeutic obstacle. This review examines light‐activated nanoplatforms combining photothermal and photodynamic therapies to overcome this challenge. Through rational design, these systems enable spatiotemporal control, enhanced tumor targeting, and synergistic antitumor efficacy.
Xianghui Duan, Gangcui Li, Hong Wang, Yanan Zhou, Hai Du, Qin Sun, Fulan Zhao, Luyin Yang, Pan Liang, Wei Ren   +9 more
wiley   +1 more source

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

BMJ
Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Zhou S, Li P, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Yao G, Fan Y, Lin J, Zhu X, Xu B.   +29 more
europepmc   +1 more source

Exceptional and Durable Complete Response to Ado-Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: A Case Report. [PDF]

Cureus
Tashima Y, Araki Y, Araki S, Tahara Y, Tanaka F.   +4 more
europepmc   +1 more source

India's Health Diplomacy: Advancing Pharmaceutical and MedTech Leadership in the Global South

World Medical &Health Policy, Volume 18, Issue 1, March 2026.
ABSTRACT Health diplomacy has become a pivotal aspect of India's engagement with the Global South, intertwining foreign policy, public health, and global collaboration to address disparities while pursuing strategic interests. India's pharmaceutical industry, which accounts for nearly 20% of the world's generics, has positioned the nation as the ...
Gaurav Chanderprakash Mittal, Vijay Kumar Chattu, Prakash Narayanan, Rahul Clare, Cherian Varghese   +4 more
wiley   +1 more source

An Integrated NMR Approach for Evaluating Linker-Payload Conjugation with Monoclonal Antibodies. [PDF]

Bioconjug Chem
Ghini V, Siciliano S, Querci L, Angiolini L, Truglio GI, Cini E, Piccioli M, Petricci E, Turano P.   +8 more
europepmc   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, Volume 117, Issue 3, Page 749-758, March 2026.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source

In vivo detection of HER2-positive breast cancer and sentinel lymph node metastasis using activatable ICG-conjugated Trastuzumab. [PDF]

Front Oncol
Liu Y, Isa M, Nakajima T.
europepmc   +1 more source

The fc fragment of IgMs binds C1q to activate the first step of the classical complement pathway, while inhibiting complement‐dependent cytotoxicity

The FEBS Journal, Volume 293, Issue 5, Page 1358-1375, March 2026.
Multimeric IgM‐fragment crystallizable region (Fc) fragments retain the ability to bind C1q and initiate the classical complement pathway, leading to C4 activation and deposition in vitro. However, the Fc cores can also inhibit complement‐dependent cytotoxicity by competing with surface‐bound antibodies for C1q engagement.
Andrea J. Pinto, Anne Chouquet, Isabelle Bally, Véronique Rossi, Nicole M. Thielens, Chantal Dumestre‐Pérard, Renate Kunert, Christine Gaboriaud, Wai Li Ling, Jean‐Baptiste Reiser   +9 more
wiley   +1 more source

²²⁵Ac-NOTA-trastuzumab human dosimetry using inter-radionuclide and biological half-life based allometric extrapolation method. [PDF]

EJNMMI Res
Almaslamani M, Kim K, Kim KI, Lim I, Kim HA, Woo SK.   +5 more
europepmc   +1 more source